Cargando…
Treatment of experienced and naïve patients with hepatitis C: focus on telaprevir
Telaprevir (TVR) is an orally available protease inhibitor of the hepatitis C virus that in association with pegylated interferon and ribavirin (PR) was shown to improve the rates of sustained virological response and potentially reduce treatment duration in adult patients with chronic hepatitis C g...
Autores principales: | D’Ambrosio, Roberta, Aghemo, Alessio, Colombo, Massimo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3484502/ https://www.ncbi.nlm.nih.gov/pubmed/23118525 http://dx.doi.org/10.2147/BTT.S20673 |
Ejemplares similares
-
Limited Utility of ITPA Deficiency to Predict Early Anemia in HCV Patients with Advanced Fibrosis Receiving Telaprevir
por: Aghemo, Alessio, et al.
Publicado: (2014) -
Hepatitis C Viral Evolution in Genotype 1 Treatment-Naïve and Treatment-Experienced Patients Receiving Telaprevir-Based Therapy in Clinical Trials
por: Kieffer, Tara L., et al.
Publicado: (2012) -
Ribavirin Impairs Salivary gland function During Combination Treatment With Pegylated Interferon Alfa-2a In HEpatitis C patients
por: Aghemo, Alessio, et al.
Publicado: (2011) -
Treatment of Patients With HCV Related Cirrhosis: Many Rewards With Very Few Risks
por: D’Ambrosio, Roberta, et al.
Publicado: (2012) -
Hepatocellular Carcinoma in Patients with a Sustained Response to Anti-Hepatitis C Therapy
por: D’Ambrosio, Roberta, et al.
Publicado: (2015)